Efalizumab in the treatment of chronic plaque psoriasis: Experiences from the largest psoriasis treatment centre in Denmark

British Journal of Dermatology

Volumn 156, Issue SUPPL. 2, 2007, Pages 7-11

  Kragballe, Knud ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chronic plaque psoriasis; Denmark; Efalizumab

Indexed keywords

ALEFACEPT; BETAMETHASONE; BIOLOGICAL FACTOR; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTHROPATHY; ARTICLE; DENMARK; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; PAPULAR RASH; PATIENT SELECTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; RECURRENT DISEASE; RISK; SCREENING; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PATIENT SELECTION; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 33947285110     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07763.x     Document Type: Article

References (14)

1. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153:486-97.
2. de Korte J, Sprangers MA, Mombers FM et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9:140-7.
3. Griffiths CE, Clark CM, Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess Rep 2000; 4:1-125.
4. Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2007; 29:49-66.
5. van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006; 20:639-50.
6. Griffiths CE, Iaccarino L, Naldi L et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006; 24:S72-8.
7. Lomholt G. Prevalence of skin diseases in a population; a census study from the Faroe Islands. Dan Med Bull 1964; 11:1-7.
8. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981; 61:344-6.
9. Sterry W, Stingl G, Langley RGB et al. CLinical Experience Acquired with Raptiva® (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial. J Dtsch Dermatol Ges 2006; 4:947-60.
10. Gottlieb AB, Gordon KB, Lebwohl MG et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3:614-24.
11. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
12. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425-33.
13. Gisondi P, Giglio MD, Girolomoni G. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. J Dermatol Treat 2006; 17:172-5.
14. Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005; 24:19-27.